Patent Docket P1154R2

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of Goddard et al. Serial No.: 09/202,054 Filed: December 7, 1998 For: Human Toll Homologues	Group Art Unit: 1644 Examiner: M. Tung **CERTIFICATE OF MAILING** I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Assistant Commissioner of Patents, Washington, D.C. 20231 on April 4, 2001 Diane L. Marschang Diane L. Marschang

RESPONSE TO NOTICE TO COMPLY AND PRELIMINARY AMENDMENT

BOX SEQUENCE
Assistant Commissioner of Patents
Washington, D.C. 20231

Sir:

Responsive to the *Notice to Comply* mailed February 27, 2001, please enter the following amendment.

In the Specification:

On page 7, in the paragraph appearing on lines 8-23, please amend the text to read as follows:

--- Figure 7 Domain function of TLR2 in signaling. **a.** Illustrations of various TLR2 constructs. TLR2-WT, the full-length epitope-tagged form of TLR2, TLR2-Δ1 and -Δ2 represent a truncation of 13 or 141 amino acids at the carboxyl terminus, respectively. CD4-TLR2, a human CD4-TLR2 chimera replacing the extracellular domain of TLR2 with amino acids 1-205 of human CD4. ECD, extracellular domain; TM, transmembrane region; ICD, intracellular domain. **b.** C-terminal residues critical for IL-1R (SEQ ID NO:31) and TLR2 (SEQ ID NO:32) signal transduction. Residue numbers are shown to the right of each protein. Arrow indicated the position of the TLR2-Δ1 truncation. *, residues essential for IL-1R signaling (Heguy *et al.*, J. Biol. Chem. 267, 2605-2609 [1992]; Croston *et al.*, J. Biol. Chem. 270, 16514-16517 [1995])l I, identical amino acid; :, conservative changes. **c.** TLR-R2 variants fail to induce NF-κB in response to LPS and LBP. 293 cells were transiently transfected with pGL3.ELAM.tk and expression vectors encoding full-length TLR2 or TLR2 variants as indicated. The cells were also transfected with a CD14 expression plasmid (+mCD14) or with a control plasmid (-mCD14). Equal expression of each protein is confirmed by Western blot using either anti-gD or CD4 antibody (bottom).